Comparison of bortesomib-based induction regimens with other treatment modalities in patients with newly diagnosed systemic light chain amyloidosis ineligible for autologous stem cell transplantation

Q4 Medicine

Cellular Therapy and Transplantation Pub Date : 2022-01-26 DOI:10.18620/ctt-1866-8836-2021-10-3-4-38-45

O. Kudyasheva, O. Pirogova, V. Porunova, S. Tolstova, A. Smirnova, I. Moiseev, A. Kulagin

引用次数: 0

Abstract

Olga V. Kudyasheva, Olga V. Pirogova, Valentina V. Porunova, Svetlana V. Tolstova, Anna G. Smirnova, Ivan S. Moiseev, Alexander D. Kulagin RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantology, Pavlov University, St. Petersburg, Russia Comparison of bortesomib-based induction regimens with other treatment modalities in patients with newly diagnosed systemic light chain amyloidosis ineligible for autologous stem cell transplantation Cellular Therapy and Transplantation (CTT). Vol. 10, No. 3-4, 2021 doi: 10.18620/ctt-1866-8836-2021-10-3-4-38-45 Submitted: 30 November 2021, accepted: 17 December 2021

查看原文本刊更多论文

以硼索菌单抗为基础的诱导方案与其他治疗方式在新诊断的不适合自体干细胞移植的全身轻链淀粉样变性患者中的比较

Olga V. Kudyasheva, Olga V. Pirogova, Valentina V. Porunova, Svetlana V.托尔斯泰，Anna G. Smirnova, Ivan S. Moiseev, Alexander D. Kulagin RM戈尔巴乔夫，圣彼得堡巴甫洛夫大学儿童肿瘤学、血液学和移植研究所以硼索菌单抗为基础的诱导方案与其他治疗方式在新诊断的不适合自体干细胞移植的全身轻链淀粉样变性患者中的比较。第10卷，第3-4号，2021 doi: 10.18620/ctt-1866-8836-2021-10-3-4-38-45提交:2021年11月30日，接受:2021年12月17日

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cellular Therapy and Transplantation Medicine-Transplantation

CiteScore

0.60

自引率

0.00%

发文量